Application of XOLAIR® (Omalizumab) in adolescent refractory chest tightness variant asthma.
Eur Rev Med Pharmacol Sci
; 26(16): 5829-5834, 2022 Aug.
Article
in English
| MEDLINE | ID: covidwho-2044338
ABSTRACT
BACKGROUND:
Asthma can manifest in a variety of clinical phenotypes like cough variant asthma, chest tightness variant asthma (CTVA), and masked asthma. Patients with CTVA usually have a singular or primary complaint of chest tightness, which is often overlooked or misdiagnosed due to the lack of characteristic asthma symptoms. We hereby report a case of CTVA managed by omalizumab. CASE REPORT A 15-year-old female patient reported to us with repeated coughing persisting for 3 weeks. Initial treatment with standard asthma drugs had minimal effect. Later during the disease, chest tightness became the primary symptom, and she was managed with steroids, ß2 receptor agonists, and leukotriene receptor agonists but without complete relief. Based on clinical signs and symptoms, the response to baseline drugs, and results of bronchial provocation test, the diagnosis was revised to CTVA, and the patient was started on Omalizumab in addition to baseline drugs, which significantly improved her condition.CONCLUSIONS:
CTVA is difficult to diagnose due to its insidious symptoms and poor characteristics. Improper treatment can lead to uncontrolled disease, negative psychological issues, and reduced quality of life. Comprehensive assessment of children's airway inflammation level, lung function, bronchial provocation test, and responsiveness to drug therapy should be performed for accurate diagnosis. Omalizumab in combination with standard drugs can significantly improve the outcomes of CTVA.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Asthma
/
Anti-Asthmatic Agents
Type of study:
Case report
/
Diagnostic study
/
Prognostic study
Topics:
Long Covid
/
Variants
Limits:
Female
/
Humans
Language:
English
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
Pharmacology
/
Toxicology
Year:
2022
Document Type:
Article
Affiliation country:
Eurrev_202208_29522
Similar
MEDLINE
...
LILACS
LIS